Evidence map›Paper›PMID 38004414›Full record

ArticlePharmaceuticals (Basel, Switzerland)2023

IL12/23 Blockade with Ustekinumab as a Treatment for Immune-Related Cutaneous Adverse Events.

Stephanie L Gu, Tara Maier, Andrea P Moy, Stephen Dusza, David M Faleck, Neil J Shah, Mario E Lacouture

Open access · goldAbstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Systemic treatment of immune checkpoint inhibitor-induced psoriasis: Inference-based guidance.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025
    Pooled it
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Stephanie L GuDermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA.
Tara MaierDermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA.
Andrea P MoyDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Stephen DuszaDermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA.ORCID 0000-0002-0747-2479
David M FaleckGastroenterology, Hepatology, and Nutrition Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0002-8245-9653
Neil J ShahDepartment of Medicine, Weill Cornell Medical College, New York, NY 10021, USA.ORCID 0000-0001-5752-6212
Mario E LacoutureDermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA.
Memorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748NCI NIH HHS P30-CA008748
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

biologicsdermatologic adverse eventsimmune-related adverse eventsimmune-related cutaneous adverse eventsustekinumab

Identifiers

PMID38004414
PMCPMC10674871
OpenAlexW4388221647

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.